Immunocore Stock Gets Weaker EPS Estimate from HC Wainwright

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) – Equities research analysts at HC Wainwright cut their Q1 2027 earnings per share (EPS) estimates for Immunocore in a note issued to investors on Tuesday, November 10th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn $0.17 per share for the quarter, down from their previous estimate of $0.18. HC Wainwright currently has a “Buy” rating and a $80.00 price objective on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($0.04) per share. HC Wainwright also issued estimates for Immunocore’s Q2 2027 earnings at $0.26 EPS, Q4 2027 earnings at $0.52 EPS and FY2027 earnings at $1.34 EPS.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings data on Friday, November 6th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.11). The company had revenue of $102.22 million for the quarter, compared to analyst estimates of $152.09 million. Immunocore had a negative net margin of 7.48% and a negative return on equity of 7.96%.

A number of other equities analysts have also weighed in on the company. Wall Street Zen lowered Immunocore from a “buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Weiss Ratings restated a “sell (e+)” rating on shares of Immunocore in a research report on Thursday, October 15th. TD Cowen raised shares of Immunocore to a “strong-buy” rating in a research note on Monday, August 24th. JPMorgan Chase & Co. began coverage on Immunocore in a report on Friday, August 21st. They set an “overweight” rating and a $50.00 price target on the stock. Finally, Mizuho upped their price target on Immunocore from $34.00 to $35.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Immunocore currently has a consensus rating of “Moderate Buy” and a consensus price target of $53.00.

Immunocore Stock Performance

Shares of NASDAQ IMCR opened at $32.38 on Wednesday. The company has a quick ratio of 4.44, a current ratio of 4.62 and a debt-to-equity ratio of 0.94. The stock has a market capitalization of $1.67 billion, a price-to-earnings ratio of -49.81 and a beta of 0.82. The stock’s fifty day simple moving average is $31.46 and its 200 day simple moving average is $31.70. Immunocore has a 52-week low of $27.50 and a 52-week high of $40.71.

Institutional Trading of Immunocore

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC lifted its holdings in shares of Immunocore by 30.9% during the first quarter. Janus Henderson Group PLC now owns 594,712 shares of the company’s stock worth $17,919,000 after buying an additional 140,308 shares during the last quarter. Braidwell LP acquired a new stake in shares of Immunocore in the second quarter worth $16,552,000. Renaissance Technologies LLC grew its stake in shares of Immunocore by 16.4% in the first quarter. Renaissance Technologies LLC now owns 164,000 shares of the company’s stock worth $4,945,000 after acquiring an additional 23,100 shares during the last quarter. Alps Advisors Inc. increased its position in Immunocore by 32.7% during the third quarter. Alps Advisors Inc. now owns 68,246 shares of the company’s stock worth $2,067,000 after acquiring an additional 16,826 shares during the period. Finally, Public Employees Retirement System of Ohio bought a new position in Immunocore during the second quarter worth $2,145,000. Institutional investors and hedge funds own 84.50% of the company’s stock.

Immunocore News Roundup

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: Shares crossed above their 200-day moving average, a potentially supportive technical signal, despite the earnings miss referenced in the report. Immunocore shares cross above 200-day moving average
• Positive Sentiment: HC Wainwright maintained its Buy rating and an $80 price target—about 147% above the cited $32.38 share price—though the target was reduced from $100. HC Wainwright rating and price target
• Neutral Sentiment: Immunocore presented at the Society for Immunotherapy of Cancer’s 2026 annual meeting; the available article is a slideshow and does not detail specific new clinical findings. SITC 2026 presentation slideshow
• Negative Sentiment: HC Wainwright trimmed its 2027 EPS forecasts for Q1 ($0.17 from $0.18), Q2 ($0.26 from $0.29) and full-year 2027 ($1.34 from $1.36). It raised its Q4 estimate to $0.52 from $0.49, but the overall revisions were lower.
• Negative Sentiment: The cut in HC Wainwright’s price target from $100 to $80 may weigh on sentiment, even with its Buy rating retained.

About Immunocore

Immunocore is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body’s T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach. The company’s marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma.